OncoQR ML's Vaccine Platform Closes the Final Gap in the Immunological Attack Against Cancer
Vienna, Austria September 21, 2017 / B3C newswire / -- OncoQR ML GmbH announced today that even a single therapeutic vaccine based on its proprietary S-TIR™ platform technology, is able to induce the killing of tumor target expressing cells by …